Antibiotic Laboratory, Servicio de Bacteriología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
J Antimicrob Chemother. 2014 Jan;69(1):111-6. doi: 10.1093/jac/dkt324. Epub 2013 Aug 13.
The epidemiology of invasive Haemophilus influenzae has changed in recent years. β-Lactamase-negative ampicillin-resistant (BLNAR) invasive isolates have recently been described in Europe but their clinical significance is unclear. Our main goal was to determine whether invasive H. influenzae remains susceptible to β-lactam antibiotics indicated in the treatment of invasive infections.
The antibiotic susceptibility of 307 invasive H. influenzae isolates to seven β-lactam antibiotics was determined by microdilution and interpreted by EUCAST and CLSI breakpoints. We also identified the bla genes, the amino acid substitutions in the transpeptidase domain of penicillin-binding protein 3 (PBP3), the molecular epidemiology of invasive BLNAR isolates by PFGE and MLST, and the time-kill curves of two isolates with PBP3 mutations conferring reduced susceptibility to aminopenicillins and cephalosporins.
Of the invasive isolates, 86.6% were non-typeable and 62% were isolated from adults. Decreased susceptibility to β-lactams was due to the BLNAR genotype (gBLNAR; 19.2%) and to β-lactamase production (16.9%). Susceptibility rates to amoxicillin/clavulanic acid, cefotaxime, cefixime and imipenem were greater than 98%. Of 18 gBLNAR non-typeable isolates studied by MLST, 15 different STs were obtained. Amoxicillin and cefotaxime were bactericidal after 2 and 4 h of incubation, respectively.
Invasive H. influenzae disease was mainly due to non-typeable isolates infecting adults, and the most common mechanism of β-lactam resistance was mutations in the transpeptidase domain of PBP3. The gBLNAR non-typeable isolates were genetically diverse. The majority of invasive H. influenzae remained susceptible to third-generation cephalosporins; amoxicillin and cefotaxime were bactericidal in two gBLNAR isolates.
近年来,侵袭性流感嗜血杆菌的流行病学发生了变化。最近在欧洲描述了β-内酰胺酶阴性氨苄西林耐药(BLNAR)侵袭性分离株,但它们的临床意义尚不清楚。我们的主要目标是确定侵袭性流感嗜血杆菌是否仍然对治疗侵袭性感染的β-内酰胺抗生素敏感。
通过微量稀释法测定 307 株侵袭性流感嗜血杆菌对 7 种β-内酰胺抗生素的药敏性,并根据 EUCAST 和 CLSI 折点进行解释。我们还通过 PFGE 和 MLST 鉴定了 bla 基因、青霉素结合蛋白 3(PBP3)转肽酶结构域的氨基酸取代、BLNAR 侵袭分离株的分子流行病学,以及对 2 株具有降低对氨芐西林和头孢菌素敏感性的 PBP3 突变的分离株的时间杀菌曲线。
侵袭性分离株中,86.6%为不可分型,62%分离自成人。β-内酰胺耐药性降低是由于 BLNAR 基因型(gBLNAR;19.2%)和β-内酰胺酶产生(16.9%)所致。阿莫西林/克拉维酸、头孢噻肟、头孢克肟和亚胺培南的敏感性率大于 98%。18 株 gBLNAR 不可分型分离株经 MLST 研究,获得了 15 种不同的 ST。阿莫西林和头孢噻肟分别在孵育 2 和 4 小时后具有杀菌作用。
侵袭性流感嗜血杆菌病主要由感染成人的不可分型分离株引起,β-内酰胺耐药的最常见机制是 PBP3 转肽酶结构域的突变。gBLNAR 不可分型分离株具有遗传多样性。大多数侵袭性流感嗜血杆菌仍对第三代头孢菌素敏感;阿莫西林和头孢噻肟在 2 株 gBLNAR 分离株中具有杀菌作用。